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Abstract
Ubiquitylation is fundamental for the regulation of the stability and function of p53 and c-Myc. The E3 ligase Pirh2 has been
reported to polyubiquitylate p53 and to mediate its proteasomal degradation. Here, using Pirh2 deficient mice, we report
that Pirh2 is important for the in vivo regulation of p53 stability in response to DNA damage. We also demonstrate that c-
Myc is a novel interacting protein for Pirh2 and that Pirh2 mediates its polyubiquitylation and proteolysis. Pirh2 mutant mice
display elevated levels of c-Myc and are predisposed for plasma cell hyperplasia and tumorigenesis. Consistent with the role
p53 plays in suppressing c-Myc-induced oncogenesis, its deficiency exacerbates tumorigenesis of Pirh22/2 mice. We also
report that low expression of human PIRH2 in lung, ovarian, and breast cancers correlates with decreased patients’ survival.
Collectively, our data reveal the in vivo roles of Pirh2 in the regulation of p53 and c-Myc stability and support its role as a
tumor suppressor.
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Introduction
Protein ubiquitylation is essential for a broad spectrum of
cellular processes including nuclear export, endocytosis, transcrip-
tional regulation, DNA damage repair and proteasomal degrada-
tion [1]. Impairment of the ubiquitylation process has been
associated with a variety of human diseases including autoimmu-
nity, immunodeficiency, inflammation and cancer [2,3].
One well established role for ubiquitylation in cancer is its
function in regulating the stability and function of the tumor
suppressor p53 and the oncogene c-MYC, two proteins with major
roles in human malignancies [2–4]. Monoubiquitylation of p53
serves to signal its nuclear export as well as its mitochondrial
translocation, while p53 polyubiquitylation targets it for protea-
somal degradation. Remarkably, p53 is targeted for ubiquitylation
by several ubiquitin E3 ligases including Pirh2 (Rchy1), Mdm2/
Hdm2, Cop1, E6/E6AP, ARF-BP1, Synoviolin and by atypical
E3 ligases including E4F1 [5].
Similar to p53, ubiquitylation is critical for the regulation of the
function and stability of c-MYC, an oncoprotein frequently
overexpressed in various human cancers including breast and
ovarian cancer [6,7]. The ubiquitin ligases FBW7, SKP2 and
ARF-BP1/HectH9 have been shown to mediate c-MYC ubiqui-
tylation. While c-MYC polyubiquitylation by FBW7 leads to its
proteasomal degradation, its polyubiquitylation by ARF-BP1
increases its transcriptional activity. c-MYC ubiquitylation by
SKP2 has been shown to mediate both its transactivation activity
and proteasomal degradation [2,6]. Interestingly, some of the E3
ligases important for the regulation of c-Myc also regulate p53
function. SKP2 negatively regulates p53 by suppressing its
acetylation by p300 while ARF-BP1 suppresses p53 through its
polyubiquitylation and proteolysis [8,9]. Furthermore, FBW7 loss
of function has been reported to attenuate p53 activity [10].
The identification of multiple E3 ligases that regulate the
function and stability of p53 and c-MYC and the possible
involvement of some of these E3 ligases in the regulation of both
p53 and c-Myc have raised questions regarding the physiological
functions of these E3 ligases. Despite the identification of Pirh2 as
an E3 ligase that polyubiquitylates p53 in cell culture assays, its in
vivo functions remain unknown. Here we report that mice deficient
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for Pirh2 are viable but display elevated levels of p53 and apoptosis
in response to DNA damage. We also demonstrate that c-Myc is a
novel Pirh2 interacting protein and that Pirh2 regulates c-Myc
expression levels by mediating its polyubiquitylation and proteol-
ysis. Consistent with this novel Pirh2 function, mice mutant for
Pirh2 show elevated levels of c-Myc and increased risk for plasma
cell hyperplasia, gammaglobulinemia, and tumorigenesis. In
accordance with the role of p53 in suppressing c-Myc oncogenesis,
its inactivation considerably increases spontaneous cancer suscep-
tibility of Pirh2 deficient mice. We also report that the expression
of PIRH2 is reduced in various human cancers and that lower
levels of PIRH2 expression correlate with decreased survival of
patients with lung, breast or ovarian cancer.
Collectively, these data support a role for Pirh2 in the in vivo
regulation of p53 functions, demonstrate its negative regulation of
the oncoprotein c-Myc, and support its role as a novel tumor
suppressor.
Results
Pirh2 Is Dispensable for Development
Although p53 is a substrate for ubiquitylation by several E3-
ligases, to date only Mdm2 is known to be required for p53
regulation in vivo as its deficiency leads to embryonic lethality in a
p53-dependent manner [11–13]. To characterize the physiological
functions of Pirh2, an E3 ligase previously reported to poly-
ubiquitylate p53 and regulate its stability [14], we generated Pirh2
mutant mice (Figure S1A and S1B). Western blot analysis
indicated loss of Pirh2 protein in Pirh22/2 cells (Figure S1C). By
contrast to Mdm2 deficiency [11–13], loss of Pirh2 did not affect
embryonic development. Pirh22/2 mice were born in a Mendelian
ratio, were fertile and did not present any apparent developmental
defects compared to their wildtype (Wt) littermates. Analysis of total
cell numbers as well as the different cell subpopulations in thymus,
spleen, lymph nodes (LN) and bone marrow (BM) of 6 to 8 week-
old Pirh22/2 mice revealed no significant differences compared to
Wt littermates (Figure S1D and S1E). In addition, [3H] thymidine
incorporation assay indicated that loss of Pirh2 had no significant
effect on the in vitro proliferation of T- and B-cells from 6 to 8
week-old Pirh22/2 mice (Figure S1F). These data indicate that
Pirh2 is dispensable for embryonic and postnatal development.
Pirh2 Regulates p53 Turnover in Response to DNA
Damage
p53 is essential for several cellular processes including apoptosis,
cell cycle, senescence and metabolism and its stability is regulated
by various proteins including the E3 ligases Mdm2, Cop1, and
ARF-BP1 [5,15]. To determine the role Pirh2 plays in the in vivo
regulation of p53, we examined p53 levels and functions in Pirh2
deficient mice and cells. Splenocytes and thymocytes from Pirh22/2
and Wt mice were irradiated ex-vivo, and the levels of p53 expression
and activation were determined by Western Blot analysis.
Untreated Pirh22/2 cells displayed mildly increased expression of
p53 compared to Wt controls (Figure 1A). However, untreated
Pirh22/2 cells, similar to Wt controls, displayed no detectable
expression of the p53 transcriptional targets p21, bax, and Puma
(Figure 1A). We examined the effect of Pirh2 deficiency on
irradiation (IR) induced p53 expression and have observed that
irradiation of Pirh22/2 splenocytes resulted in higher expression
levels of p53 and its targets p21, bax, and Puma compared to Wt
controls (Figure 1A and 1B). Consitent with the reported
increased transcription of pirh2 in response to p53 activation in
mouse embryonic fibroblasts (MEFs) [14], Pirh2 mRNA was
found to increase by 1.5 fold at 1 to 4 h post irradiation of
splenocytes (Figure S2A). To examine the in vivo effects of Pirh2
loss on the expression of p53, Pirh22/2 mice and their Wt
littermates were subjected to whole-body irradiation (6 Gc) and
their tissues were collected at different time points post-
irradiation (0–12 h). Immunohistochemistry (IHC) examination
of p53 expression indicated that while p53 was undetectable
in spleen, thymus, intestinal crypts and liver from untreated
Pirh22/2 and Wt mice, the frequency of cells expressing p53 in
these organs was significantly higher post-IR of Pirh22/2 mice
compared to Wt controls (Figure 1C and 1D, Figure S2B–S2D).
We next examined the effect of PIRH2 deficiency on P53 level
using human RKO cells in which PIRH2 was knocked down by a
tetracycline-inducible system [16]. Similar to murine cells,
deficiency of PIRH2 in RKO cells only slightly increased P53
level under untreated conditions, but this increase was more
pronounced post-IR (Figure S2E).
Phosphorylation of p53 is critical for its stability and functions
[17]. For instance, in response to DNA damage, p53 is
phosphorylated on Serine 15 (p53-S15) by a number of kinases
including ATM, DNA-PK and ATR and phosphorylation of this
p53 site, together with others, is important for its stability and
functions [17]. To further examine the effect of Pirh2 deficiency
on p53 stability and function, we examined by Western blotting
the level of p53-S15 in Pirh22/2 and Wt cells. While, the level of
p53-S15 was similarly low in untreated Pirh22/2 and Wt
splenocytes, it was significantly higher in irradiated Pirh22/2 cells
compared to Wt controls (Figure S3A). Similarly, IHC analysis
indicated no differences in the levels of p53-S15 in spleen of
untreated Pirh22/2 mice and Wt controls; however a marked
increased expression of this phosphorylated form of p53 was
observed post whole-body irradiation of Pirh22/2 mice compared
to Wt controls (Figure S3B).
We next examined the effect of PIRH2 expression on the level
of S15-p53 using H1299 cells transiently transfected with
expression vectors for MDM2 or PIRH2 and either wildtype
p53, p53 S15A or p53 S15D. The presence of Alanine (A) at
residue 15 of p53 prevents p53 phosphorylation at this site while
the presence of Asparatic acid (D) at this site mimics its constitutive
Author Summary
Tumor suppressors and oncogenes play critical roles in
cancer development. The tumor suppressor p53 and the
oncogene c-MYC are among the most frequently dereg-
ulated genes in human cancer, and their ubiquitylation
mediated by several E3 ligases is critical for their turnover
and their functions. P53 has been shown to be ubiquity-
lated by Pirh2; however, the physiological significance of
this modification of p53 remains unknown. In this study
we have generated mice deficient for Pirh2 and have
observed that loss of Pirh2 results in a higher level of p53
and cell death, especially in response to radiation.
Remarkably, we also identified that Pirh2 interacts with
c-Myc and mediates its polyubiquitylation and degrada-
tion. c-Myc accumulates in the absence of Pirh2 and this
accumulation is accompanied by increased tumorigenesis
of Pirh2-deficient mice. We also report that dual deficiency
of Pirh2 and p53 synergizes cancer development. Exam-
ination of the expression level of PIRH2 in human cancers
indicated that its lower expression level associates with
poor survival of patients with lung, ovarian, or breast
cancers. Collectively, these data indentify Pirh2 as a novel
tumor suppressor involved in the regulation of both p53
and c-Myc.
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phosphorylation. Western blot analysis indicated that overexpres-
sion of MDM2 or PIRH2 decreased the level of wildtype p53
(Figure S3C). Consistent with previous data, overexpression of
MDM2 was able to decrease the stability of p53 S15A and p53
S15D [17–19]. Interestingly, while overexpression of PIRH2
resulted in decreased expression of both forms of p53, its effect was
more pronounced on p53 S15D. Collectively, these data support a
role for Pirh2 in the regulation of p53.
Pirh2 Deficiency Leads to Elevated Irradiation-Induced
Apoptosis
p53 plays central roles in IR-induced apoptosis; therefore we
have examined the effect of Pirh2 deficiency on the levels of
apoptosis under untreated and DNA damage conditions. Spleno-
cytes and thymocytes from Pirh22/2 and Wt mice were either
untreated or irradiated (6 Gc) and their apoptotic levels examined
using the AnnexinV/PI assay (Figure 2A). We also examined the
Figure 1. Pirh2 Negatively Regulates p53 Turnover in Response to DNA Damage. (A) Time course immunoblot analysis of the expression of
p53, p21, Bax, Puma and Pirh2 in response to irradiation (6 Gc) of Wt and Pirh22/2 splenocytes. p53 level was quantified based on scanning by
densitometry using ImageJ and normalized by b-actin level. p53 fold increase is indicated. Data are representative of four independent experiments.
(B) Splenocytes from Wt and Pirh22/2 mice were IR treated (6 Gc) and their RNA extracted at time 0, 1 and 4 h post-IR. Quantitative RT-PCR analysis
was performed to assess gene expression of Puma and p21 and was normalized to actin mRNA. Fold changes of mRNA expression in Wt and Pirh22/2
compared to their time 0 h is shown. Student’s t test was used for statistical analysis. P,0.001 for time 0 h vs. 1 h or 4 h for Wt (n = 4) and Pirh22/2
(n = 5). Error bars represent SD. (C) Wt and Pirh22/2 6–8 week-old mice were irradiated (6 Gc), sacrificed at different times post-IR and the level of p53
expression in spleen was examined by IHC. Data are representative of three independent experiments. (D) p53 positive cells from spleen (upper
panel) and thymus (lower panel) of untreated (n = 3) and irradiated (n = 3) mice were counted from 10 different fields for each time point. Student’s t
test was used for statistical analysis. *: P,0.05. Error bars represent SD.
doi:10.1371/journal.pgen.1002360.g001
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level of apoptosis in thymus, spleen and intestinal crypts from
whole-body irradiated (6 Gc) mice using TUNEL assay and
cleaved caspase 3 IHC (Figure 2B and 2C, Figure S3D and S3E).
Our data indicated no increased level of spontaneous apoptosis in
the absence of Pirh2; however consistent with the elevated IR-
induced expression of p53 and its proapototic target genes Bax and
Puma in the absence of Pirh2, IR-induced cell death was
significantly elevated in Pirh22/2 cells and mice compared to Wt
controls. These data demonstrate that Pirh2 deficiency results in
elevated IR-induced apoptosis.
Pirh2 Interacts with the Oncoprotein c-Myc
In our search for novel Pirh2 interacting proteins we identified
interaction of Pirh2 and c-Myc. We observed that human PIRH2
and c-MYC reciprocally co-immunoprecipitate upon overexpres-
sion in HEK293 cells (Figure 3A). Endogenous interaction of
murine Pirh2 and c-Myc was confirmed in NIH3T3 cells where
immunoprecipitation of Pirh2 pulled down c-Myc and immuno-
precipitation of c-Myc pulled down Pirh2 (Figure 3B).
We next examined whether PIRH2 and c-MYC interaction was
direct and characterized the domains involved in this interaction.
We performed Glutathione S-transferase (GST) pull-down assays
using purified GST or His-fusion proteins of the full length or
fragments of PIRH2 and c-MYC. These pull-down assays
indicated interaction of PIRH2 amino acids (aa) 138–261 with
the N-terminus of c-MYC (aa 120–160) that contains MYCboxII
(MBII) but not with N-terminus of c-MYC (aa 1–69) that contains
MYCboxI (MBI) (Figure 3C and 3E, Figure S4A). Notably, MBII
(aa 128–143) is important for c-MYC proteasomal degradation,
transcriptional repression and activation and for controlling c-
MYC transformation ability [20]. Pull-down experiments using
His-C-terminus of c-MYC (aa 353–434) demonstrated the
interaction of this region of c-MYC with the N-terminus of
PIRH2 (aa 1–137) (Figure 3D and 3E). These data reveal c-MYC
as a novel interacting protein for PIRH2 and indicate the
importance of different domains of c-MYC and PIRH2 for this
interaction.
Pirh2 Mediates c-Myc Polyubiquitylation
Polyubiquitylation of c-Myc is critical for the regulation of its
stability and functions [2,6]. Our observation that c-MYC
interacted with the E3 ligase PIRH2 raised the possibility that it
might be a target for PIRH2 mediated ubiquitylation. We
examined this hypothesis in HEK293T cells that overexpress
HA-Ubiquitin (Ub), human c-MYC, and/or either human full
length PIRH2 or a PIRH2 lacking the ring finger domain
(PIRH2DR). 48 h post-transfection, immunoprecipitation followed
by Western Blot analysis revealed high-molecular-weight c-MYC
species where full length PIRH2, but not PIRH2DR, were
overexpressed in the presence of c-MYC and HA-Ub
(Figure 4A). Anti-HA immunoblot of c-MYC immunoprecipitates
confirmed that the observed high-molecular-weight c-MYC
species in the presence of the full length PIRH2 were indeed
due to its polyubiquitylation. Our data also demonstrated the
requirement for the RING finger domain of PIRH2 for its
polyubiquitylation of c-MYC (Figure 4B). Similarly, we examined
the ability of PIRH2 to polyubiquitylate T58A c-MYC as
phosphorylation of c-MYC at this site is critical for its
polyubiquitylation by FBW7. Consitent with our finding that
MBI that contains T58 is dispensible for the interaction c-MYC-
PIRH2, PIRH2 was able to ubioquitylate T58A mutant c-MYC
(Figure S4B). We also performed in vitro ubiquitylation assays and
observed that PIRH2 directly polyubiquitylates c-MYC (Figure 4C
and 4D).
We next examined the role of Pirh2 in the ubiquitylation of the
endogenous c-Myc using Pirh22/2 and Wt B-cells. Anti-IgM
activated B-cells were pre-treated for 3 h with the proteasome
inhibitor MG132, and c-Myc immunoprecipitates were examined
for their levels of ubiquitylation using anti-c-Myc and anti-
ubiquitin antibodies. Pirh2 deficiency resulted in reduced level of
both high-molecular-weight and polyubiquitylated forms of c-Myc
(Figure 4E and 4F). Taken together, these data identified c-Myc as
a novel substrate for Pirh2-mediated polyubiquitylation.
Pirh2 Mediates c-Myc Proteolysis and Its Absence Leads
to Accumulation of c-Myc Protein
Since c-Myc polyubiquitylation can control its turnover, we
examined the steady state levels of c-Myc in Wt and Pirh22/2
MEFs in the presence of the protein biosynthesis inhibitor
cycloheximide (CHX). These studies indicated that while less
than 40% of c-Myc remained in Wt MEFs 1 h post-CHX
treatment, near 80% of c-Myc remained in Pirh22/2 MEFs
(Figure 5A). Similarly, knockdown of human PIRH2 in RKO cells
resulted in increased c-MYC stability (Figure 5B).
Because Pirh2 interacted with c-Myc and mediated its
polyubiquitylation and proteolysis, we examined the effect of its
deficiency on the level of c-Myc protein. We first assessed by
Western blotting the expression of c-Myc in B-cells from young (6–
8 weeks old) Pirh22/2 mice and their Wt littermates. c-Myc
protein level was significantly increased in naı¨ve and in anti-IgM
activated Pirh22/2 B-cells compared to Wt controls (Figure 5C).
Immunohistochemistry analysis of the expression level of c-Myc
protein in spleen from young Pirh22/2 and Wt mice also showed
increased c-Myc level in the absence of Pirh2 (Figure 5D).
Quantitative real time PCR analysis of cDNA from Pirh22/2 and
Wt splenocytes indicated that despite the increased protein
expression of c-Myc in Pirh22/2 cells, c-Myc mRNA abundance
was not significantly affected compared to Wt controls (Figure 5E).
However, examination of c-Myc transcriptional targets indicated
that the RNA expression level of E2f1, Ccna2, Ccnd2 and Brca1 was
significantly increased while Mcl-1 RNA expression was repressed
in accordance with the elevated levels of c-Myc in Pirh22/2 cells
(Figure 5E). Increased level of Ccnd2 protein was also observed in
splenocytes from young Pirh22/2 mice compared to Wt littermates
(Figure 5F). Western blot examination of c-Myc expression in
various tissues from young Pirh22/2 mice and Wt littermates
indicated increased c-Myc level in the absence of Pirh2, with the
highest increase observed in spleen, testis and mammary glands
(Figure 5F and 5G).
The tumor suppressor p19ARF has been shown to be
upregulated in response to high, but not to low, levels of
deregulated c-Myc [21]. Using Western blotting we evaluated
the level of p19ARF in cells and tissues from young Pirh22/2 mice
and their Wt littermates. The level of p19ARF protein was found
elevated in Pirh22/2 activated B-cells and in tissues that express
high levels of c-Myc (e.g. spleen, testis, mammary glands)
(Figure 5C, 5G and 5J).
We next examined whether the loss of human PIRH2 would
also lead to increased level of c-MYC protein. Western blot
analysis indicated that similar to Pirh2 deficiency in mice, knock
down of the human PIRH2 in RKO cells significantly increased
the protein expression level of c-MYC (Figure 5H). Conversely,
overexpression of human PIRH2 in RKO cells downregulated
their protein level of c-MYC (Figure 5I).
Since Skp2 and Fbw7 mediate c-Myc polyubiquitylation and
proteasomal degradation [2,6,22,23], we examined their expres-
sion levels in Pirh22/2 cells and Wt controls. Western blot analyses
indicated no difference in the expression levels of Skp2 in spleen,
Role of Pirh2 in Cancer
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liver and kidney from Pirh22/2 and Wt mice, while Fbw7
expression was barely detectable in these organs independently of
the genotypes (Figure 5J). We next sought to examine whether
PIRH2-c-MYC complex may also contains SKP2 or FBW7.
While Western blotting analysis of whole cell lysate of RKO cells
showed that these cells expressed PIRH2, SKP2 and FBW7;
Figure 2. Increased Radiosensitivity in the Absence of Pirh2. (A) Determination of the viability of Pirh22/2 and Wt splenocytes and
thymocytes 6 h post ex vivo radiation (0–6 Gc). Viability was determined using Annexin V/PI assay. (B) Time course analysis of apoptosis using TUNEL
assay was performed on thymus sections from whole body irradiated (6 Gc) Wt and Pirh22/2 6–8 week-old mice. (C) Positive cells for cleaved caspase
3 (casp3) in Wt and Pirh22/2 thymus and spleen sections were counted in 10 different fields for each time point. The data shown in A and C are
representative of at least three independent experiments. Student’s t test was used for statistical analysis. *: P,0.05. Error bars represent SD.
doi:10.1371/journal.pgen.1002360.g002
Role of Pirh2 in Cancer
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Figure 3. Characterization of the Interaction of PIRH2 and c-MYC. (A) Interaction of human PIRH2 and c-MYC. HEK293T cells were transfected
with expression plasmids encoding PIRH2 and c-MYC as indicated. Immunoprecipitation (IP) was performed with anti-PIRH2 or anti-c-MYC antibody
and analyzed by immunoblot (IB). (B) NIH3T3 cells were lysed and IP performed with antibodies against murine Pirh2 or murine c-Myc, followed by IB
analysis. A portion of the cell lysate corresponding to 3% of the input for IP was subjected to IB analysis. WCL: whole cell lysate. (C) PIRH2 interacts
with the N-terminus of c-MYC. GST pull-down assays of GST-PIRH2 fusion proteins with c-MYCboxII (120–160 aa). Labeled lanes reflect loaded
material (L), column flow-through after wash (W) and eluate (E). (D) GST pull-down assays of GST-PIRH2 with His-c-MYC (353–434 aa) protein. Star
indicates GST-PIRH2 proteins. (E) Schematic representation of the interacting regions of PIRH2 and c-MYC. MBI: c-MYCboxI, MBII: MYCboxII, NLS:
nuclear localization signal, bHLH: Basic region and Helix–loop–helix, LZ: leucine zipper.
doi:10.1371/journal.pgen.1002360.g003
Role of Pirh2 in Cancer
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PIHR2 immunoprecipitation from these cells pulled down c-
MYC, but failed to pull down SKP2 or FBW7 (Figure S4C).
Therefore SKP2 and FBW7 are not part of the PIRH2-c-MYC
complex.
Collectively, these data demonstrate that Pirh2 deficiency leads
to increased level of c-Myc protein and that Pirh2 regulates c-Myc
stability.
PIRH2 Expression Is Downregulated in Human Cancer
PIRH2 was reported to be overexpressed in lung and prostate
cancer [24,25]; however, to date no human pathologies have been
associated with its decreased expression. To assess whether
reduced Pirh2 expression associates with cancer, we examined
PIRH2 expression in primary human cancers using microarray
studies that associated mRNA levels to patient outcome. Median
Figure 4. PIRH2 Polyubiquitylates c-MYC and Mediates Its Proteasomal Degradation. (A, B) Intracellular ubiquitylation assay. HEK293T
cells were transfected with expression plasmids encoding Wt or deleted RING (DR) human PIRH2, c-MYC and HA-tagged ubiquitin (HA-Ub) as
indicated. IP using anti-c-MYC antibody were subjected to IB analysis with anti-c-MYC antibody (A) or anti-HA antibody (B). 3% of the input for IP was
subjected to IB analysis (A). WCL: whole cell lysate. (C, D) In vitro ubiquitylation assay. 6xHis tagged ubiquitin, human ubiquitin activating enzyme E1,
UBE2D2/UbcH5b, GST-PIRH2 and GST-c-MYC were used to assess PIRH2 mediated c-MYC ubiquitylation in vitro. Ubiquitylated c-MYC proteins were
visualized by Western Blot using anti-c-MYC antibody (C) or anti-Ub antibody (U0508) (D). Star indicates GST-c-MYC degradation species. (E)
Splenocytes from 8 week-old Wt and Pirh22/2 mice (young) or from 11 month-old Pirh22/2 mice (old) were cultured in the presence or absence of
anti-IgM and/or MG132 for 3 h. Cells were lysed and subjected to IP with anti-c-Myc antibody (N262), and precipitates were subjected to anti-c-Myc
(C33) IB analysis. Despite the elevated c-Myc level in samples from Pirh22/2mice, the amount of ubiquitylated c-Myc protein remained very low. (F) In
vivo ubiquitylation assay. Splenocytes were harvested from Wt and Pirh22/2 mice at 8 weeks of age and cultured in the presence or absence of anti-
IgM and/or MG132 for 3 h. Pirh22/2 cell lysates were adjusted to contain an equivalent amount of c-Myc protein compared to Wt controls. IP
performed with anti-c-Myc antibody was subjected to IB analysis with anti-Ub.
doi:10.1371/journal.pgen.1002360.g004
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Figure 5. Increased c-Myc Protein Level in Pirh2 Mutant Cells and Mice. (A) Half-life determination of c-Myc protein in the presence or
absence of Pirh2. Wt and Pirh22/2 MEFs were deprived of serum for 48 h, stimulated by re-exposure to serum for 4 h, and then incubated in the
presence of CHX for the indicated times. Cell lysates were subjected to immunoblot analysis with antibodies for c-Myc or b-actin. c-Myc level was
quantified based on scanning by densitometry using ImageJ and normalized by b-actin level. c-Myc fold increase is indicated. These data are
representative of 2 independent experiments. (B) Half-life determination of the level of human c-MYC protein in the presence or absence of PIRH2.
Tetracyclin inducible PIRH2 knockdown RKO cells (PIRH2 KD RKO-11) were grown in the absence or presence of tetracyclin for 72 h and CHX was
added to these cells for the indicated times. Representative Western blot analysis of the effect of knockdown of PIRH2 on the expression level of c-
MYC in RKO cells is shown. c-MYC level was quantified based on scanning by densitometry using ImageJ and normalized by b-actin level. c-Myc fold
increase is indicated. (C) Immunoblot analysis of c-Myc, p19ARF and Pirh2 expression in splenocytes from 6 week-old Pirh22/2 and Wt littermates. Cell
extracts were prepared at 0, 0.5, 1 and 2 h post anti-IgM stimulation. These data are representative of 4 independent experiments. (D) Sections from
Wt and Pirh22/2 spleens were stained with anti-c-Myc antibody (Bar = 50 mm). (E) Quantitative real time PCR was performed to assess the mRNA level
of c-Myc and its transcriptional targets E2f1, Ccna2, Brca1 and Mcl-1 in spleen from 10 to 13 month-old Wt (n = 4) and Pirh22/2 (n = 12) mice. mRNA
expression was normalized to actin mRNA. Fold changes of mRNA expression is shown. Student’s t test was used for statistical analysis. Stars indicate
P,0.008; ns: not significant. Error bars represent SD. (F) Immunoblot analysis of c-Myc, Ccnd2 and Pirh2 expression in spleen from Pirh22/2 andWt 10
month-old mice. (G) Immunoblot analysis of c-Myc, p19ARF and Pirh2 expression in testis, mammary glands, lung and bulbourethral glands from 8
week-old Pirh22/2 and Wt mice. *: non specific. (H) Western blot analysis of the expression of c-MYC in tetracyclin inducible PIRH2 knockdown RKO
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dichotomization was used to identify patients with high- and low-
PIRH2 expression levels. We found that lower levels of PIRH2
mRNA were associated with reduced patient survival in breast
cancer [26,27] (Figure 6A), ovarian cancer [28,29] (Figure 6B) and
squamous cell carcinomas of the lung [30,31] (Figure 6C).
The expression level of PIRH2 mRNA was also surveyed in
microarray studies of human cancer using the Oncomine database
[32]. Expression of PIRH2 mRNA was significantly reduced in
ovarian clear cell adenocarcinoma [33], adult germ cell tumors
[34] and invasive bladder cancer [35] compared to controls
(Figure S5). These data indicate the high prognostic significance of
PIRH2 expression for patients with these tumor types.
Pirh2 Mutation Leads to Plasma Cell Hyperplasia,
Gammaglobulinemia, Kidney Failure, and Premature
Death
Deregulated c-Myc has been associated with a number of
diseases including plasma cell hyperplasia, gammaglobulinemia,
kidney failure and cancer development [7,36–38]. Monitoring of
cohorts of Pirh2 mutant and Wt mice indicated that both Pirh22/2
and Pirh2+/2 mice had reduced lifespan compared to Wt
littermates (Figure 7A). Necropsy of Pirh2 mutant mice indicated
that these mutants developed a lymphoproliferative disorder
characterized by plasma cell hyperplasia. 100% of sick Pirh2
mutants presented splenomegaly while lymphadenopathy was
observed in 40% and 20% of sick Pirh22/2 and Pirh2+/2 mice
respectively (Figure 7B and 7C). Hematoxylin and Eosin (H&E)
staining of spleen and lymph nodes from sick Pirh2 mutant mice,
together with in-touch blood smears, illustrated the presence of
plasma cells with large basophilic cytoplasm, eccentric nuclei with
clock face appearance and occasional multiple Russell bodies
(Figure 7D–7G), all typical features of well differentiated plasma
cells. FACS analysis and IHC staining for CD138, a marker for
plasma cells, indicated increased proportion of CD138+B2202
cells in the spleen of sick Pirh22/2 mice (Figure S6A and S6B).
Infiltration of these plasma cells was evident in regional lymph
nodes and kidneys (Figure 7E and 7G). Pirh22/2 plasma cell
perivascular infiltrates to non lymphoid organs displayed elevated
levels of c-Myc that was accompanied by increased proliferation as
indicated by their level of Ki67 (Figure S7A). Consistent with these
data and the increased expression of c-Myc in Pirh22/2
splenocytes, activated T-cells or B-cells from Pirh22/2 mice
displayed higher proliferation rates compared to Wt controls
(Figure S7B). In addition these Pirh22/2 activated cells also
displayed increased apoptosis compared to Wt controls (Figure
S7C).
As the cytokine interleukin-6 (IL-6) is important for the
differentiation and survival of plasma cells [39], and Pirh22/2
mice develop a plasma cell disorder, we next examined by ELISA
the serum level of IL-6 in Pirh22/2 mice and their controls. We
observed elevated levels of IL-6 in the serum of sick Pirh2 mutant
mice compared to Wt littermates (Figure S6D).
Macroscopic analysis of sick Pirh22/2 and Pirh2+/2 mutant
mice indicated the presence of pale kidneys in about 40% of the
cases. In order to examine the cause for this kidney defect, H&E
staining was performed on kidneys from Pirh2 mutants and Wt
littermates. Since infiltration of plasma cells was observed in
kidneys from Pirh2 mutant mice (Figure 7G), we investigated
whether the kidney defects of these mice would be associated with
immunoglobulin (Ig) deposits. Staining of kidney sections with
anti-Ig antibodies indicated the presence of glomerular Ig
deposition in Pirh22/2 and Pirh2+/2 mice but not in age matched
Wt littermates (Figure S6C).
In accordance with the plasma cell hyperplasia and the elevated
level of glomerular Ig deposition observed in Pirh2 mutant mice,
ELISA analysis of serum Ig levels of 10 to 12 month-old Pirh22/2
mice indicated that these mice suffered gammaglobulinemia.
Significantly elevated levels of IgG1, IgG2b and IgA were
observed in the serum of Pirh22/2 mice compared to their Wt
littermates (Figure S6E).
Figure 6. Downregulation of PIRH2 Associates with Short-Term Survival of Patients with Breast Cancer, Ovarian Cancer, or
Squamous Cell Carcinomas of the Lung. Datasets of cancer patients at different stages were used to test for any association between PIRH2
mRNA levels and patient outcome. PIRH2 mRNA expression is significantly down-regulated in short-term survival breast cancer patients [27]
(P=0.049, HR= 0.52, 95% CI 0.27–1.0, n = 118) (A), in short-term survival ovarian cancer patients [28] (P= 0.02; HR= 0.36–0.92) (B) and short-term
survival patients with squamous cell carcinomas of the lung [31] (P=0.11, HR = 0.67, 95% CI 0.41–1.1, n = 130) (C). HR: Hazard ratio.
doi:10.1371/journal.pgen.1002360.g006
cells (PIRH2 KD RKO-11). Representative Western blots of three independent experiments are shown. (I) Western blot analysis of the effect on c-MYC
level of transfected human PIRH2 (hPIRH2) in RKO cells. *: non specific. (J) Representative immunoblot analyses of the level of Skp2, Fbw7 and p19ARF
in spleen, liver and kidney from 8 week-old Wt and Pirh22/2 mice. *: non specific.
doi:10.1371/journal.pgen.1002360.g005
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While plasma cells in sick Pirh2 mutant mice showed several
histological and morphological features of malignancy, their lack
of clonality as assessed by rearrangement of Ig loci, and the
polyclonal gammaglobulinemia of Pirh2 mutant mice prevented us
from characterizing the disease as a plasma cell neoplasm. These
data indicate that Pirh2 deficiency results in plasma cell
hyperplasia, gammaglobulinemia, glomerular Ig deposition and
kidney failure that likely contribute to the premature death of Pirh2
mutant mice.
Pirh2 Is a Tumor Suppressor and It Deficiency Synergizes
Tumorigenesis Associated with p53 Loss
Overexpression of ubiquitin ligases including MDM2, COP1
and ARF-BP1 has been observed in human cancer [40–42], while
downregulation of others such as FBW7 or Rnf8 promotes
tumorigenesis [2,43,44]. Monitoring of cohorts of Pirh2 mutant
mice indicated that in addition to plasma cell hyperplasia
and kidney failure, approximately 25% of Pirh22/2 and 17% of
Pirh2+/2 sick mice developed solid tumors including sarcomas,
Figure 7. Shorter Life Span and Plasma Cell Hyperplasia of Pirh2 Mutant Mice. (A) Kaplan-Meier analysis representing the percent survival
versus age in days of cohorts of Wt (n = 30), Pirh2+/2 (n = 40) and Pirh22/2 (n = 25) mice. Log-rank test, P,0.046 between Pirh2+/2 mice and Wt
controls; P,0.0001 between Pirh22/2 mice and Wt controls. (B) Representative splenomegaly associated with Pirh2 mutation. (C) Size of spleens from
Wt (n = 8), Pirh2+/2 (n = 5) and Pirh22/2 (n = 8) 10 to 12 month-old mice. Student’s t test was used for statistical analysis. Stars indicate P,0.005. Error
bars represent SD. (D) H&E staining of Pirh22/2 spleen sections showing plasma cells with Russell bodies (Bar = 20 mm). (E) H&E staining of sections
from grossly enlarged Pirh22/2 lymph nodes showing focal infiltrates of a large number of plasma cells (Bar = 50 mm; inset: bar = 20 mm). (F) Blood
smear performed on Pirh22/2 mice showing atypical plasma cells (Bar = 20 mm; inset: bar = 20 mm). (G) H&E staining of Pirh22/2 kidney sections
showing plasmacytoid aggregates infiltrating the kidney interstitium (Bar = 100 mm).
doi:10.1371/journal.pgen.1002360.g007
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Figure 8. Pirh2 Is a Tumor Suppressor That Collaborates with p53 in Suppressing Cancer. (A) Kaplan-Meier analysis representing the
percent survival versus age in days ofWt (n = 30), Pirh22/2 (n = 25), p532/2 (n = 10) and Pirh22/2p532/2 (n = 35) cohort of mice. (B) Tumor spectrum of
p532/2 and Pirh22/2p532/2 mice. Log-rank test, P,0.0001 between Pirh22/2p532/2 mice and Pirh22/2 or p532/2 controls. (C) Pirh2+/2 mammary
adenocarcinoma (H&E stain;Bar = 100 mm). This tumor is composed of a sheet of pleomorphic epithelial cells with moderate mitotic index, good
vascularization and some infiltrating acute inflammatory cells. (D) Pirh22/2 sarcoma (H&E stain; Bar = 100 mm). This tumor is composed of arrays of
fusiform cells, some of them anaplastic; the tumor also shows good vascularity and some lymphocytic infiltration. (E) Pirh22/2p532/2 mammary
adenocarcinoma (H&E stain; Bar = 500 mm). In contrast with panel C, this tumor is a well-differentiated adenocarcinoma in which acinar structures can
be seen interspersed with islets of invasive cells. (F) Pirh22/2p532/2 angiosarcomas (H&E stain; Bar = 100 mm). This tumor is mostly constituted by
malignant endothelial cells forming irregular spaces filled with red blood cells. (G) Immunoblot analysis showing elevated level of c-Myc in spleen
from 6 week-old Pirh22/2p532/2 mice compared to Wt and p532/2 controls. (H) Immunoblot analysis showing elevated level of c-Myc in Pirh22/2
mammary glands from 6 to 8 week-old mice and in Pirh22/2 mammary tumors. (I) Immunoblot analysis of the level of c-Myc and p19ARF in Wt spleen
and tumors from Pirh22/2 mice. 1: sarcoma, 2–6: lung tumors, 7: liver tumor and 8: Breast Tumor tumor. (J) Immunoblot analysis of c-Myc level in
testes from 6 week-old Wt, Pirh22/2, and Pirh22/2p532/2 mice and in Pirh22/2p532/2tumors.
doi:10.1371/journal.pgen.1002360.g008
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liver, testes, mammary and lung tumors (Figure 8C and 8D, Figure
S8A–S8D and Table S1).
P53 is the most frequently inactivated tumor suppressor in
human cancer [45], and its loss facilitates c-Myc induced
oncogenesis [46]. To examine the effect of p53 deficiency on
development and tumorigenesis of Pirh2 mutant mice, we crossed
Pirh22/2 and p532/2 mice and generated Pirh22/2p532/2 mice.
Double mutant mice were born in a Mendelian ratio and showed
no developmental defects. Remarkably, Pirh22/2p532/2 mice had
a dramatically reduced lifespan compared to p532/2 and Pirh22/2
mice with all double mutants dying before 126 days of age
compared to 230 days for p532/2 littermates (Figure 8A).
Necropsy examination of Pirh22/2p532/2 mice indicated that
60% of them died due to their tumor burden, while the cause of
death remained unknown for the remaining mutants. The tumor
spectrum of Pirh22/2p532/2 mice was significantly altered
compared to Pirh22/2 and p532/2 mutants and consisted of
adenocarcinomas, sarcomas, thymomas and T-cell lymphomas
(Figure 8B, 8E and 8F; Table S2).
Examination of cells and tissues from healthy Pirh22/2p532/2
mice indicated that these mice, similar to Pirh22/2 mice, exhibited
elevated levels of c-Myc (Figure 8G and 8J). Western blot analysis
also indicated elevated levels of c-Myc in Pirh22/2 tumors
(Figure 8H and 8I); however the majority of these tumors did
not show elevated levels of p19ARF (Figure 8I). In addition, similar
to Pirh22/2 tumors, c-Myc levels were also elevated in Pirh22/2
p532/2 tumors (Figure 8J).
These data support Pirh2 function as a tumor suppressor and
demonstrate that tumorigenesis of Pirh2 deficient mice is
exacerbated by the loss of p53.
Discussion
Ubiquitylation plays critical roles in the regulation of stability
and function of p53 and c-Myc, two of the most important tumor
suppressors and oncogenes, respectively. Several E3 ligases have
been shown to regulate p53 stability [5]; however, the physiolog-
ical functions of most of these E3 ligases have not yet been
addressed. Mdm2 is well accepted as the master regulator for p53
stability and has been demonstrated for its requirement for
embryonic and postnatal development [11–13,47]. Previous
studies also indicated that while Mdm2 is required for p53
stability due to its central role in the polyubiquitylation and
degradation of p53 [13,17], Mdm2 independent regulation of p53
degradation also exists. In this study we report that in contrast to
Mdm2 deficiency, absence of Pirh2 did not affect embryonic
development and only mildly affected p53 steady state levels.
However, in response to DNA damage and despite the presence of
other E3 ligases for p53 (e.g. Mdm2), Pirh2 deficiency resulted in
higher p53 levels in several tissues. Although, we cannot exclude a
tissue specificity for the increased IR-induced p53 expression in
the absence of Pirh2, collectively our current data indicate a role
for Pirh2 in the regulation of p53 stability in response to DNA
damage and support a model in which different E3 ligases regulate
p53 turnover in a developmental, tissue, stress or time specific
manners.
The oncogene c-MYC is frequently deregulated in human
cancer [7] and similar to p53, its stability and function are
regulated by a number of posttranslational modifications including
ubiquitylation. SKP2, FBW7 and ARF-BP1 have been demon-
strated to mediate c-MYC ubiquitylation [2,6]. In this study we
identified c-MYC as a novel interacting protein for PIRH2 and
demonstrated that this interaction requires both the N- and C-
terminal domains of PIRH2 as well as the MBII and the C-
terminal domain of c-MYC. Similar to its interaction with PIRH2,
c-MYC interaction with SKP2 also involves both its MBII and C-
terminal domain [22,23].
In this study, we also demonstrate that PIRH2 polyubiquitylates
c-MYC and that this c-Myc polyubiquitylation controls c-MYC
stability and proteolysis. Pirh2 deficient murine cells and tumors,
and human RKO cells knocked down for PIRH2, displayed
significantly elevated levels of c-Myc protein, supporting that
ubiquitylation control of c-Myc turnover is not only mediated by
Skp2 and Fbw7, but also involves Pirh2. Our in vitro data showing
that PIRH2 interacts with c-MYC and mediates its polyubiqui-
tylation strongly support a direct role for this E3 ligase in c-MYC
polyubiquitylation and degradation.
The embryonic lethality of Fbw7 mutant mice [48] and the
postnatal developmental defects of Skp2 mutants [49,50] contrast
with the normal embryonic and postnatal development observed
with Pirh2 mutants. These developmental differences, together
with the differential requirement for these E3 ligases for cancer
suppression [2,43], highlight the complex in vivo functions of these
E3 ligases.
Although c-Myc protein level was elevated in all examined
tissues of Pirh22/2 mice, spleen, testis and mammary glands
displayed the highest levels of c-Myc. In agreement with the
upregulation of p19ARF in response to high levels of deregulated c-
Myc [21], spleen, testis and mammary glands of Pirh22/2 mice
displayed increased p19ARF expression. However, p19ARF expres-
sion was not increased in Pirh22/2 tissues (e.g. lung, liver) that only
displayed a moderate elevation of c-Myc expression. As c-Myc
induced p19ARF expression results in the sequestration of mdm2 in
the nucleolus and the subsequent activation of p53 [51], it is
possible that increased levels of c-Myc and p19ARF in Pirh22/2
mice might contribute to their higher IR-induced p53 responses
compared to control littermates. However, our observation that
liver of Pirh22/2 mice display elevated IR-induced p53 expression
compared to Wt controls whithout any detectable level of p19ARF,
supports that increased IR-induced p53 expression in Pirh2
mutants can take place independently of p19ARF. Further
biochemical and genetic studies are required to determine whether
the increased expression of c-Myc and p19ARF in Pirh2 deficient
cells affects their p53 responses.
Our finding that Pirh2 polyubiquitylates c-Myc and mediates its
proteolysis, and the elevated c-Myc level associated with Pirh2
deficiency support the possibility that deregulated c-Myc in
Pirh22/2 mice may increase their cancer susceptibility. Indeed,
Pirh2 mutant mice displayed increased predisposition to develop
tumors including sarcomas, testis, mammary and lung tumors. In
accordance with the role p53 plays in suppressing c-Myc induced
oncogenesis [46], Pirh22/2p532/2 mice showed a markedly
increased cancer predisposition compared to single mutants. The
accumulation of c-Myc in Pirh2 mutant mice is also consistent with
their elevated risk for developping plasma cell hyperplasia,
gammaglobulinemia and kidney failure [36–38].
Human PIRH2 has been reported to be overexpressed in lung
and prostate cancer [24,25]. However, the human PIRH2 locus at
4q21 is lost in a diverse subset of solid tumors including epithelial
tumors of the breast and lung [52,53]. We report in this study that
PIRH2 expression is downregulated in various human cancers and
that lower PIRH2 expression correlates with decreased survival of
patients with lung squamous cell carcinomas, breast or ovarian
cancer. Interestingly, Pirh2 mutant mice also displayed increased
risk for lung and breast cancer.
The ability of the E3 ligase Pirh2 to negatively regulate IR-
induced p53 and c-Myc steady state level, together with the
increased risk for Pirh2 mutant mice to develop various
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pathologies, including cancer, all highlight the importance of this
novel tumor suppressor and demonstrate the requirement for its
tight regulation.
Materials and Methods
Generation Pirh2 Mutant Cells and Mice
E14K embryonic stem cells were electroporated with the
linearized targeting construct for Pirh2 (Figure S1) and Pirh2fl2-3-neo
ES clones identified by PCR and Southern blotting. Pirh2D2-3
ES clones lacking exon 2 and 3 and the Neomycin resistance cassette
were obtained following transient transfection of two targeted
Pirh2fl2-3-neo ES clones with CMV-Cre recombinase. Pirh2D2-3 ES
clones were used to derive two independent lines of mutant mice
(referred here as Pirh2 mutants). All mice were in 129/C57BL/6
genetic background and were maintained in the animal facility of the
Ontario Cancer Institute in accordance with the established ethical
care regulations of the Canadian Council on Animal Care. P53
mutant mice [54] were obtained from Taconic.
MEFs were derived according to standard procedures.
HEK293T cells, RKO cells and PIRH2-KD RKO clone #11
in which PIRH2 can be knocked down by a tetracycline-inducible
system [16], have been also used.
Flow Cytometry
Single cell suspensions from thymi, spleens, lymph nodes and
bone marrow of Wt and Pirh2 mutant mice were stained with the
following antibodies against the cell surface markers: CD4, CD8,
CD3, CD43, CD95, CD138, IgM, IgD, B220, and Thy1.2
(ebioscience and Pharmingen). Stained cells were analyzed by flow
cytometry using the FACScan and Cellquest software.
Cell Activation Assay
Activation of T and B-cells was performed as previously
described [55].
Quantitative Real Time PCR and Genomic PCR
Cells were harvested and total RNA isolated with Trizol (Gibco).
cDNA was generated using Invitrogen kit. SYBR green kit from
Applied Biosystems was used for Real-time PCR. The following
oligonucleotides were used: Actin (59AACAGGAAGCCCATCAC-
CATCTT39 and 59GCCCTTCCACAATGCCAAAGTT39), IL-6
(59TAGTCCTTCCTACCCCAATTTCC39 and 59TTGGTC-
CTTAGCCACTCCTTC39), c-Myc (59ATGCCCCTCAACGT-
GAACTTC39 and 59CGCAACATAGGATGGAGAGCA39),
Ccna2 (59GCCTTCACCATTCATGTGGAT39 and 59TTGCT-
GCGGGTAAAGAGACAG39), Ccnd2 (59GAGTGGGAACTGG-
TAGTGTTG39 and 59CGCACAGAGCGATGAAGGT39), E2f1
(59CAGAACCTATGGCTAGGGAGT39 and 59GATCCAGC-
CTCCGTTTCACC39), Mcl-1 (59AAAGGCGGCTGCATAAG-
TC39 and 59TGGCGGTATAGGTCGTCCTC39), p21 (59CCT-
GGTGATGTCCGACCTG59 and 59CCATGAGCGCATCG-
CAATC39), Puma (59CCTGGGTAAGGGGAGGAGT39 and 59A-
GCAGCACTTAGAGTCGCC39), Brca1 (59AAGGAGCCCGT-
GTGCTTAG39 and 59TTGCCCTAGATGTGTTGTCTT-
TT39), and Pirh2 (59CAGACTTGTGAAGACTGTAGCAC39
and 59 CGAAGATTCGTGGTTAGGCAT39). PCR were per-
formed on the Applied Biosystem 7900HT Fast Real-Time PCR
system.
GST Pull-Down Assays
Recombinant purified full length PIRH2 and its fragments were
incubated with His-c-MYC fusion proteins in an assay buffer
containing PBS (pH 7.4), 100 mM NaCl, 1 mM Benzamidine,
0.5 mM PMSF and 5 mM bME in a 1:2 molar ratio at 4uC
overnight. Then, proteins were incubated with the 100 ml of
glutathione-Sepharose beads (GE Healthcare) for an additional
2 h. The mixture was transferred to a microcolumn and was
extensively washed with the assay buffer. Bound proteins were
eluted with 30 mM reduced glutathione and detected by SDS-
PAGE and Coomassie staining
Western Blot and Immunoprecipitation Analysis
Western blot analysis was performed as previously described
[55]. The following antibodies were used: c-Myc (C33 and N262;
Santa Cruz), Ccnd2 (Santa Cruz), PIRH2 (Santa Cruz and
BETHYL laboratories), SKP2 (Santa Cruz), FBW7 (Sigma),
p19ARF (Novus and Calbiochem), and anti-b-actin (Sigma).
HEK293T cells were transfected with expression plasmids
encoding human PIRH2 (pcDNA3-hPIRH2) and c-MYC
(pcDNA3-c-MYC) using the calcium phosphate method. After
48 h, the cells were lysed in a solution containing 50 mM Tris-
HCl (pH 7.4), 150 mM NaCl, 1% Triton-X, 1 mM phenyl-
methylsulfonyl fluoride, 400 mM Na3VO4 and protease inhibitor
cocktail tablet (Roche). The cell lysates from transfected
HEK293T and non transfected NIH3T3 were centrifuged at
14,0006g for 10 min at 4uC, and the resulting supernatant was
incubated with anti-c-MYC antibody (N-262) for 2 h at 4uC.
Protein G-Sepharose (Amersham) was added to the mixture and
the sample rotated overnight at 4uC. The resin was separated by
centrifugation, washed four times with ice-cold lysis buffer, and
then boiled in SDS sample buffer. Immunoblot analysis was
performed with the anti-hPIRH2 (BETHYL laboratories) or anti-
c-MYC antibody (mouse monoclonal antibody; 9E10), horseradish
peroxidase-conjugated antibodies to mouse or rabbit immuno-
globulin G (1:10,000 dilutions, Cell Signaling) and an enhanced
chemiluminescence system (ECL, Amersham). Immunoprecipita-
tion of endogenous PIRH2 from RKO cells was performed using
anti-PIRH2 antibody from Santa Cruz (FL261). pcDNA3-
hPIRH2 was transfected in RKO cells using the calcium
phosphate method.
Intracellular Ubiquitylation Assay
HEK293T cells were transfected with expression plasmids
encoding the full length or a mutant lacking the ring finger domain
(DR) of human PRIH2 together with Wt or T58A c-MYC and
HA-tagged ubiquitin by the calcium phosphate method. After
48 h, the cells were lysed in a modified RIPA buffer as described
earlier. The cell lysates were centrifuged at 14,0006g for 10 min
at 4uC, and the resulting supernatant was incubated with anti-c-
MYC antibody (N262) for 2 h at 4uC. Protein G-Sepharose was
added to the mixture, which was then rotated overnight at 4uC.
The resin was separated by centrifugation, washed four times with
ice-cold lysis buffer, and then boiled in SDS sample buffer.
Immunoblot analysis was performed with the anti-ubiquitin (FK2;
BIOMOL international) or anti-c-MYC antibody (9E10), horse-
radish peroxidase-conjugated antibodies to mouse or rabbit
immunoglobulin G and ECL.
In Vivo Ubiquitylation Assay
Splenocytes from Wt and Pirh22/2 8 week-old mice were
cultured in the presence or absence of anti-IgM (20 mg/ml) and/or
MG132 (20 mM; calbiochem) for 3 h. Cells were then lysed in a
modified RIPA buffer as described earlier and cell lysates
immunoprecipitated with anti-c-Myc antibody (N262). The
immunocomplexes were denatured in Laemmli’s sample buffer
(25 mM Tris pH 8.3, 192 mM glycine, 0.1% SDS) to dissociate
contaminant proteins associated with c-MYC. c-MYC proteins
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were reimmunoprecipitated (2nd IP) with anti-c-Myc antibody.
The resin was separated by centrifugation, washed four times with
ice-cold lysis buffer, and then boiled in SDS sample buffer.
Immunoblot analyses were performed with the anti-ubiquitin
(FK2) or anti-c-Myc antibody (9E10), horseradish peroxidase-
conjugated antibodies to mouse immunoglobulin G and ECL.
In Vitro Ubiquitylation Assay
Human ubiquitin activating enzyme E1 and 6xHis tagged
ubiquitin were purchased from Boston Biochem. The ubiquityla-
tion reaction was performed in a volume of 20 mL in a buffer of
50 mM Tris pH 7.6, 5 mM MgCl2, 2 mM ATP, 2 mM DTT.
The reaction mixture typically contained E1 (50 ng, Calbiochem),
UBE2D2/UbcH5b (100 ng), Ubiquitin (5 mg, Sigma), Pirh2 (1 mg)
and full-length c-Myc (0.5 to 1 mg). After incubation at 30uC for
1.5 h, the reactions were stopped by addition of SDS-PAGE
sample buffer and resolved on 7.5–10% SDS-PAGE gels.
Ubiquitylated proteins were visualized and evaluated by Western
Blot using anti-c-MYC (N262) and anti-Ub antibody (U0508,
Sigma).
Immunohistochemistry
Tissues and tumors fixed in buffered formalin were processed
for paraffin-embedded sectioning at 5 mm, and stained with H&E
(Fisher). IHC was performed using anti-c-Myc (C19, Santa Cruz),
anti-cleaved caspase 3 (Cell Signaling) or Ki67 (Dako). TUNEL
staining was performed using an in situ cell death detection kit
(Boehringer Mannheim).
Microarray Data Analysis
Microarray data from public studies were downloaded from
GEO [26–30]. All data was log2 transformed and normalized
according to the original authors, with the exception of the lung
adenocarcinoma dataset, whose pre-processing has been described
elsewhere [56]. Unadjusted Cox proportional hazards models
were fit in the R statistical environment (v2.6.2) using the survival
package (v2.34). P-values were calculated using the Wald test.
Correlation analyses used Pearson’s correlation as implemented in
R (v2.6.2). Scatter- and box-plots were generated using the lattice
package (v0.17–4). Long-term (.7 years) vs. short-term survival
groups in ovarian cancer dataset [29] were analyzed using a t-test
with Welch’s adjustment for heteroscedascity. We have used all 25
long-term and all 30 short-term survival samples available from
the raw data. Analyzing only strictly long- and strictly short-term
survival samples (n = 23 and n = 27 respectively) does not change
the average expression and standard error; it only reduces the
significance to p = 0.002162. Additional data were considered
from Oncomine Research Edition v.3.6, with statistical analysis as
described previously [32].
Supporting Information
Figure S1 Pirh22/2 mice display normal immune cell develop-
ment and proliferation of T and B-cells. (A) A schematic
representation of the Pirh2 locus, the targeting construct, and the
mutant Pirh2 alleles (Pirh2fl2-3-neo, Pirh2fl2-3 and Pirh2D2-3). Exons
are indicated as boxes, loxP sites as triangles and positions of 59 and
39 probes used for Southern blot are indicated. S, Sst1 site.
Expected sizes of Sst1 DNA fragments are indicated. (B) Southern
blot analysis of Sst1 digested tail genomic DNA of a litter from
Pirh2+/2 intercrosses. 59 probe shown in (A) was used. (C) Western
blot analysis of cell extracts from Wt and Pirh22/2 splenocytes
showing loss of Pirh2 expression in mutant cells. (D) A
representative FACS analysis of thymus, spleen, LN and BM cells
from 8 week-old Wt and Pirh22/2 mice. Percentages of
populations are indicated. (E) Thymocyte and splenocyte numbers
from 6 to 10 week-old Wt (n = 6), Pirh2+/2 (n = 5) and Pirh22/2
(n = 9) mice. No significant differences were observed between Wt
and mutant mice. (F, left panel) T-cells from Wt, Pirh2+/2 and
Pirh22/2 6 to 10 week-old mice were activated using anti-CD3
and IL2 and their level of proliferation determined using [3H]
Thymidine incorporation assay. Data for 48 h and 72 h time
points are shown and are representative of 5 independent
experiments. (F, right panel) B-cells from Wt, Pirh2+/2 and
Pirh22/2 mice were activated with anti-IgM+IL4, anti-
IgM+CD40, or with LPS and their proliferation determined using
[3H] Thymidine incorporation assay. Data for 48 h time point are
shown. This result is representative of 5 independent experiments.
UT = untreated. BM: bone marrow.
(TIF)
Figure S2 Pirh2 deficiency leads to higher accumulation of p53
in response to irradiation. (A) Splenocytes from Wt and Pirh22/2
mice were IR treated (6 Gc) and their RNA extracted at time 0, 1
and 4 h post-IR. Quantitative RT-PCR analysis was performed to
assess Pirh2 expression and was normalized to actin mRNA. Fold
changes of Pirh2 mRNA expression in irradiated Wt splenocytes
compared to their untreated controls (time 0 h) is shown. Student’s
t test was used for statistical analysis. *P,0.05 compared to time
0 h. Wt (n = 4) and Pirh22/2 (n = 5). Error bars represent SD. (B,
C) 6 to 8 week-old Wt and Pirh22/2 mice either untreated or 2 h
post whole-body irradiation (6 Gc) were sacrificed and IHC was
performed to assess the level of p53 in thymus (B) and intestinal
crypts (C). Bar = 50 mm. (D) p53 positive cells in intestinal crypts
(left) and liver (right) of untreated (n = 3) and irradiated (n = 3) Wt
and Pirh22/2 mice were counted from 10 different fields for each
time point. Student’s t test was used for statistical analysis.
* P,0.0005. Error bars represent SD. (E) A representative
Western blot of three independent experiments showing the
expression of p53 following tetracyclin induced PIRH2 knock-
down in the human RKO cells.
(TIF)
Figure S3 Absence of Pirh2 leads to higher levels of Serine 15
phosphorylated p53 and increased apoptosis in response to
irradiation. (A) Time course immunoblot analysis of the expression
level of Serine 15 phosphorylated p53 (S15-p53), total p53, Bax
and Pirh2 in response to irradiation (6 Gc) of Wt and Pirh22/2
splenocytes. *: non specific. (B) 6 to 8 week-old Wt and Pirh22/2
mice either untreated or 1 h post whole-body irradiation (6 Gc)
were sacrificed and IHC was performed to assess the level of S15-
p53 in their spleen. Bar = 50 mm. (C) H1299 cells were
cotransfected with either pcDNA3.1, pcDNA3.1-Mdm2 or
pcDNA3.1-PIRH2 and a p53 expression vector (Wt, S15A,
S15D). Lysates prepared 40 h post-transfection were examined by
Western blotting using the indicated antibodies. (D) 6 to 8 week-
old Wt (n = 3) and Pirh22/2 mice (n = 3) were subjected to whole-
body irradiation (6 Gc) and the levels of apoptosis in thymus at
different time points post-IR were examined using active caspase 3
(casp3) and IHC. Bar = 100 mm. (E) Active casp3 positive cells in
intestinal crypts of untreated (0 h) and irradiated Wt (n = 3) and
Pirh22/2 (n = 3) mice were counted from 10 different fields for
each time point. Student’s t test was used for statistical analysis.
* P,0.005. Error bars represent SD.
(TIF)
Figure S4 PIRH2 does not interact with SKP2 or FBW7 and
ubiquitylates c-MYC independently of its phosphorylation at T58.
(A) PIRH2 does not interact with c-MYCbox I (MBI). GST pull-
down assays of GST-PIRH2 fusion protein with His-c-MYC boxI
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(1–69 aa) protein. Labeled lanes reflect loaded material (L),
column flow-through after wash (W) and eluate (E). (B)
Intracellular ubiquitylation assay. HEK293T cells were trans-
fected with expression plasmids encoding Wt human PIRH2,
HA-tagged ubiquitin (HA-Ub), c-MYC Wt or c-MYC T58A as
indicated. IP using anti-c-MYC antibody were subjected to IB
analysis with anti-c-MYC antibody (left panel). 3% of the input
for IP was subjected to IB analysis with anti-cMYC and anti-
PIRH2 (right panel). WCL: whole cell lysate. (C) Representative
IP/Western blot data for three independent experiments showing
that IP of PIRH2 from human RKO cells pulls down c-MYC but
not SKP2 or FBW7. IP: immunoprecipitation. WCL: whole cell
lysate.
(TIF)
Figure S5 Reduced levels of PIRH2 mRNA in human cancers.
(Left panel) Data [33] provided by Oncomine Research Edition
v.3.6 [32] show significant downregulation of PIRH2 mRNA in
ovarian clear cell adenocarcinoma compared to normal ovary
(* P= 5.161026; t-test). (E, Middle panel) Data [34] provided by
Oncomine Research Edition v.3.6 show significant downregula-
tion of PIRH2 mRNA in adult germ cell tumors compared to
normal testis (* P= 1.7 10218; t-test). (E, Right panel) Data [35]
provided by Oncomine Research Edition v.3.6 show significantly
downregulated PIRH2 mRNA level in invasive compared to
superficial bladder cancer (* P= 4.5 1025; t-test).
(TIF)
Figure S6 Accumulation of CD138+B2202 cells, glomerular
immunoglobulin deposition and elevated serum immunoglobulins
in Pirh2 mutant mice. (A) Cells from spleen of 11 month-old Wt and
Pirh22/2 littermates were stained with anti-CD138 (a marker for
normal and malignant plasma cells), anti-B220 (a marker for B-
cells) and FACS analysis was performed. The percentage of
CD138+B2202 cells is indicated. (B) Liver sections from a 10
month-old Pirh22/2 mouse were stained with anti-CD138. A sheet
of CD138+ cells infiltrating the liver is shown. Bar = 35 mm. (C)
Glomerular Immunoglobulin deposition in 10 to 12 month-old
Pirh22/2 and Pirh2+/2 mice. Immunoglobulin deposits in kidneys
from the autoimmune Lpr mice are show as positive controls. (D)
Elevated level of IL-6 in the serum of 10 month-old Pirh22/2 mice
compared to Wt littermates. Student’s t test was used for statistical
analysis. *P,0.005. Error bars represent SD. (E) ELISA analysis of
the level of IgG1, IgG2b and IgA serum Ig in 10 to 12 month-old
Pirh22/2 and WT mice. * P,0.05. Bar = 50 mm.
(TIF)
Figure S7 Plasma cell infiltration to non lymphoid organs of
Pirh22/2 mice. IHC of the lung of a Pirh22/2 mouse showing
structurally normal lung with perivascular plasma cell infiltrates.
The infiltrates stain positive for c-Myc and Ki67. Lung section of
Wt littermates are shown as controls. Left panels: bars = 500 mm.
Right panels: bars = 35 mm. (B) FACS analysis of CFSE dilution
profiles. LPS induced proliferation of CFSE-labeled B-cells (top
panel) and Anti-CD3 induced proliferation of CFSE-labeled T-
cells (lower panel) were examined 72 h post activation. Data are
representative of four independent experiments. (C) Cell death of
cells described in panel B was determined using AnnexinV/PI
staining 72 h post-activation. Student’s t test was used for statistical
analysis. *: P,0.005. Error bars represent SD.
(TIF)
Figure S8 Tumorigenesis of Pirh2 mutant mice. (A, B) H&E
staining of adenosquamous cell mammary carcinoma from a
Pirh22/2 mouse. This tumor is composed of islets of malignant
epithelial cells, with invasion to surrounding connective tissue;
keratin pearls are evident within the tumor (panel A: upper and
lower left corners). Higher magnification shows the glandular
(panel B: lower right) and squamous cellular phenotypes (panel B:
upper left and right). (A, Bar = 500 mm; B, Bar = 100 mm). (C, D)
H&E staining of a Pirh22/2 lung neoplasm showing a solitary
nodular mass with a well-differentiated adenomatous pattern. This
lesion has well-defined borders, is highly vascularized and is
surrounded by normal lung with occasional mononuclear
inflammation foci. (C, Bar = 500 mm; D, Bar = 100 mm).
(TIF)
Table S1 Plasma Cell Hyperplasia and Tumor Development in
Pirh2 Mutant Mice.
(PDF)
Table S2 Tumor types in Pirh22/2p532/2 Mutant Mice.
(PDF)
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